112例造血干细胞移植总结报告  

Retrospective analysis of 112 cases of hematopoietic stem cell transplantation

作　　者：欧英贤[1] 白海[1] 王存邦[1] 潘耀柱[1] 达万明[2] 魏亚明[1] 王晓靖[1] 欧剑峰[1] 吕桂玲[1] 路继红[1] 

机构地区：[1]兰州军区兰州总医院全军血液病中心,甘肃兰州730050 [2]解放军总医院血液科,北京100853

出　　处：《西北国防医学杂志》2004年第1期22-24,共3页Medical Journal of National Defending Forces in Northwest China

基　　金：甘肃省自然科学基金资助项目 (ZS0 1 1 -A2 5- 0 80 -Y)

摘　　要：目的 :评价造血干细胞移植 (HSCT)治疗血液病的临床疗效及并发症。方法 :112例血液病患者行HSCT ,其中自体HSCT(auto -HSCT) 52例 ,混合HSCT(mixed -HSCT) 3 3例 ,异基因HSCT(allo -HSCT) 2 7例。结果 :随访平均 64个月 (2月～ 2 0年 ) ,62例 (55.4% )无病存活 ,其中 :auto -HSCT2 7/ 52例 (51.9% ) ,mixed -HSCT19/ 3 3例 (57.6% ) ,allo -HSCT16/ 2 7例 (59.3 % )。 51例(45.5% )死亡 ,其中 :auto -HSCT :18/ 52例 (3 4 .6% )复发死亡 ;7/ 52例 (13 .5% )移植相关死亡 ;mixed -HSCT :19/ 3 3例 (2 4.2 % )复发死亡 ;6/ 3 3例 (18.2 % )移植相关死亡 ;allo -HSCT :3 / 2 7例 (11.1% )复发死亡 ;2 / 2 7例 (7.4% )GVHD引起肝功衰竭死亡 ;6/2 7例 (2 2 .1% )移植相关死亡。结论 :HSCT治疗疗效确切 。Objective:To evaluate the clinical effic acy and complication of hematopoietic stem cell transplantation(HSCT) in 112 patients with hematopoietic disease. Methods:112 pa tients with hematopoietic disease received HSCT, including 52 cases of auto-HSCT,33 cases of mixed-HSCT, 27 cases of allo-HSCT.Resul ts:The median follow-up duration was 64(2-240) months,62 cases (55.4%) of all were alive in a disease-free situation, including:auto-HSC T:27/52 (51.9%), mixed-HSCT 19/33(57.6%), allo-HSCT 16/27 (59.3%).51 patients died,including:auto-HSCT:18/55(34.6%) patients died from relapse and 7/25(13.5%)from transplantation related mortality(TRM);mixed-HSCT:8/33(24.2%) patients died from TRM and 6/33(18.2%)from relapse;allo-HSCT:3/27(11.1%)patients died from relapse,6/27(22.1%)from TRM,and 2/27(7.4%)from liv er aGVHD.Conclusion:HSCT had a good efficacy in the treatment of hematopoietic disease, especially in malignant hema topoietic disease and can enhance the disease-free survival.

关 键 词：造血干细胞移植 血液病 总结 

分 类 号：R55[医药卫生—血液循环系统疾病]